Quality of prescribing for schizophrenia: Evidence from a national audit in England and Wales

European Neuropsychopharmacology

Volumn 24, Issue 4, 2014, Pages 499-509

  Patel, Maxine X ^a   Bishara, Delia ^b   Jayakumar, Simone ^c   Zalewska, Krysia ^c   Shiers, David ^c   Crawford, Mike J ^d   Cooper, Stephen J ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; Dose; Prescribing; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL DOCUMENTATION; MEDICATION COMPLIANCE; MIDDLE AGED; MONOTHERAPY; OPTIMAL DRUG DOSE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REMISSION; SCHIZOPHRENIA; SEX DIFFERENCE; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT; DRUG MISUSE; MENTAL HEALTH; ADOLESCENT; ADVERSE EFFECTS; CLINICAL AUDIT; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; DRUG RESISTANCE; ENGLAND; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; PSYCHOTIC DISORDERS; WALES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENGLAND; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WALES; YOUNG ADULT;

EID: 84895886385     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.01.014     Document Type: Article

References (42)

1. Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, Fervaha G, Remington G. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur. Neuropsychopharmacol. 2013, 23:1017-1022.
2. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008, 41:24-28.
3. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2011, 25:567-620.
4. Bishara D, Olofinjana O, Sparshatt A, Kapur S, Taylor D, Patel MX. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J. Clin. Psychopharmacol. 2013, 33:329-335.
5. Bitter I, Treuer T, Dyachkova Y, Martenyi F, McBride M, Ungvari GS. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur. Neuropsychopharmacol. 2008, 18:170-180.
6. BMJ Group and RPS Publishing (2013) British National Formulary-65th ed.
7. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
8. Carlson C, Hornbuckle K, DeLisle F, Kryzhanovskaya L, Breier A, Cavazzoni P. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur. Neuropsychopharmacol. 2006, 16:366-375.
9. Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J. Psychopharmacol. 2007, 21:657-664.
10. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr. Res. 2007, 89:91-100.
11. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv. 1998, 49:196-201.
12. Faries D, scher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26.
13. Fearon P, Kirkbride JB, Morgan C, Dazzan P, Morgan K, Lloyd T, Hutchinson G, Tarrant J, et al. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychol. Med. 2006, 36:1541-1550.
14. Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 2010, 13:1115-1125.
15. Fleischhacker WW, Heikkinen T, Olie JP, Landsberg W, Dewaele P, McQuade RD, Hennicken D. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur. Psychiatry 2008, 23(Suppl. 2):S114-S115.
16. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J. Clin. Psychiatry 2004, 65:1377-1388.
17. Healthcare Quality Improvement Partnership. 2013. The Transparency Agenda and NCAPOP. http://www.hqip.org.uk/transparency-agenda-and-the-national-clinical-audit-and-patient-outcomes-programme/.
18. Humberstone V, Wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust. N. Z. J. Psychiatry 2004, 38:240-245.
19. Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr. Serv. 2007, 58:489-495.
20. Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr. Bull. 2002, 26:411-414.
21. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. 2012, 5:CD008016.
22. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012, 379:2063-2071.
23. Lewis S, Davies L, Jones P, Barnes T, Murray R, Kerwin R, Taylor D, Hayhurst KP, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol. Assess. 2006, 10:1-182.
24. Matthiasson P, Costa DC, Erlandsson K, Waddington W, Visvikis D, Cullum I, Cobb AM, Ell PJ, Kerwin RW, Travis MJ. Relationship between dopamine D2 receptor occupancy and clinical response in amisulpride augmentation of clozapine non-response. J. Psychopharmacol. 2001, 15:S41.
25. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
26. Meltzer HY. Treatment-resistant schizophrenia-the role of clozapine. Curr. Med. Res. Opin. 1997, 14:1-20.
27. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, nil Yagcioglu AE, Small JG. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2008, 69:274-285.
28. National Collaborating Centre For Mental Health (2011) Psychosis With Coexisting Substance Misuse: Assessment and Management in Adults and Young People, vol. 120: Rcpsych Publications.
29. National Institute for Clinical Excellence Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). Clin. Guid. 2009, 82. http://www.nice.org.uk/.
30. Patel MX, Young C, Samele C, Taylor DM, David AS. Prognostic indicators for early discontinuation of risperidone long-acting injection. Int. Clin. Psychopharmacol. 2004, 19:233-239.
31. Patel MX. Clinician hesitation prior to clozapine initiation: is it justifiable?. Br. J. Psychiatry 2012, 201:425-427.
32. Paton C, Barnes TR, Cavanagh MR, Taylor D, Lelliott P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br. J. Psychiatry 2008, 192:435-439.
33. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can. J. Psychiatry 2001, 46:334-339.
34. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin. Ther. 1998, 20:1203-1217.
35. Reilly S, Planner C, Hann M, Reeves D, Nazareth I, Lester H. The role of primary care in service provision for people with severe mental illness in the United Kingdom. PLoS One 2012, 7:e36468.
36. Royal College of Psychiatrists. 1996. Health of the Nation Outcome Scales (HoNOS). http://www.rcpsych.ac.uk/training/honos.aspx.
37. Royal College of Psychiatrists Report of the National Audit of Schizophrenia (NAS) 2012, 2012. Healthcare Quality Improvement Partnership, London.
38. Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, Chung EK, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br. J. Clin. Pharmacol. 2004, 58:178-183.
39. Taylor D, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic. A meta analysis. Acta Psychiatr. Scand. 2012, 125:15-24.
40. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J. Clin. Psychiatry 2003, 64:30-34.
41. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr. Bull. 2002, 28:31-42.
42. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur. Psychiatry 2004, 19:56-58.